Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | PRF1 | P14222 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16179669 | 0.93 | KDR (0.32) | KDRGPR84S1PR1PRF1KDM4E | |
| SCHEMBL16179620 | 0.89 | KDR (0.34) | ALDH1A1KDRGPR84S1PR1PRF1 | |
| SCHEMBL17476949 | 0.89 | ALDH1A1 (0.33) | ALDH1A1LMNAHTTGPR84PDE4B | |
| SCHEMBL17476913 | 0.89 | GRIN2B (0.34) | ALDH1A1LMNAHTTGPR84PDE4B | |
| SCHEMBL17476888 | 0.88 | ALDH1A1 (0.33) | ALDH1A1LMNAHTTPDE4B | |
| SCHEMBL17476867 | 0.87 | KDR (0.32) | KDRGPR84S1PR1PRF1 | |
| SCHEMBL17477015 | 0.83 | PDE4B (0.39) | ALDH1A1LMNAHTTPDE4BKDM4E | |
| SCHEMBL17477017 | 0.83 | PDE4B (0.39) | ALDH1A1LMNAHTTKDRPDE4B | |
| SCHEMBL17476914 | 0.82 | GRIN2B (0.34) | ALDH1A1GPR84KDM4E | |
| SCHEMBL17476950 | 0.82 | GPR84 (0.32) | ALDH1A1GPR84KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9527832-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2016-12-27 | — | — | US | disclosed |
| EP-2986600-A1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2014170020-A1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2014-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | ALDH1A1 507/4885LMNA 2348/4885HTT 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.